Dr. Finn on Results of RESOURCE Study in Liver Cancer

Richard Finn, MD, associate professor of Medicine at the UCLA David Geffen School of Medicine, discusses results of the RESOURCE study in advanced liver cancer.

In the past decade, sorafenib (Nexavar) has been the only active systematic agent in the treatment of patients with advanced liver cancer. Efforts to improve sorafenib thus far have failed in trials of both frontline and second-line settings.

RESOURCE, a large phase III, double-blind, placebo controlled randomized study, evaluated regorafenib (Stivarga) in patients with advanced liver cancer after progression on sorafenib. The primary endpoint for this study was overall survival (OS), with median progression-free survival, median time to disease progression and disease-control rates as secondary endpoints.

Regorafenib demonstrated an improvement in median OS, 10.6 months, as compared with the placebo arm at 7.8 months. All secondary endpoints were met as well.